Apolipoprotein B antisense inhibition--update on mipomersen

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Dyslipidemia, a major risk factor for cardiovascular disease (CVD), is often managed with statins and lifestyle changes.
• Familial hypercholesterolemia (FH) patients may require LDL-C apheresis when medications are insufficient.
• Emerging therapies target cholesterol synthesis and absorption, including antisense oligonucleotides (ASOs).

Purpose of the Study:

• To provide an overview of the apolipoprotein B antisense oligonucleotide (apoB ASO) approach for dyslipidemia management.
• To discuss the potential role of mipomersen, a synthetic apoB ASO, in lowering low-density-lipoprotein cholesterol (LDL-C).

Main Methods:

• Review of ASO mechanism: binding to target mRNA and inducing degradation.
• Investigation of mipomersen in homozygous/heterozygous FH and high-risk hypercholesterolemic patients.
• Analysis of Phase II and III clinical trial data for mipomersen efficacy.

Main Results:

• Mipomersen targets the mRNA of apolipoprotein B-100 (apoB-100), a key component of LDL particles.
• Clinical studies demonstrated a 25-47% reduction in LDL-C levels in patients treated with mipomersen.
• ASOs induce degradation of target mRNAs, leading to reduced protein levels.

Conclusions:

• Mipomersen represents a promising therapeutic strategy for dyslipidemia, particularly in high-risk populations.
• The apoB ASO approach offers a potential new avenue for lipid-lowering therapy.
• Further research may solidify mipomersen's role as an additional treatment option for managing cholesterol levels.